MedTrace Logo

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-04-13

Study results available
· View outcomes & findings →

Summary

Phase 1 - Pharmacokinetics in Patients with Impaired Renal Function

Conditions

  • Impaired Renal Function

Interventions

DRUG

ELX-02

ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Eloxx Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2019-07-30
Completion
2019-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03776539 on ClinicalTrials.gov